

UNIVERSITY OF CHICAGO GRAND ROUNDS PROGRAM

“Immunotherapy: Revolutionizing the Way We Treat Hematologic Malignancies”
“The Rapidly Expanding Field of Immunotherapy for Cancer”

TUESDAY, SEPTEMBER 15, 2015

Activity Agenda

- 6:30 PM: Registration
- 6:45 PM: Presentations
- 7:45 PM: Conclusion & Q/A

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists and any other healthcare professionals that manage patients with hematologic malignancies.

Learning Objectives

At the conclusion of this activity, participants should be able to:

“Immunotherapy: Revolutionizing the Way We Treat Hematologic Malignancies”

1. Summarize the data supporting the use of immunotherapy in hematologic malignancies
2. Describe forms of immune therapy for hematologic malignancies:
 - Monoclonal antibodies
 - Checkpoint blockade
 - Cellular Therapies

“The Rapidly Expanding Field of Immunotherapy for Cancer”

1. Describe the elements of an effective anti-tumor immune response
2. Outline current immunotherapy strategies
3. Review data from completed immunotherapy combinations and describe future clinical trials

Accreditation Statement

The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Educational Grants/Commercial Support

This CME certified activity has not requested or received any type of commercial support or funding from commercial interests. This includes, but is not limited to, pharmaceutical companies and medical device manufacturers.

Faculty Presenters:

Michael R. Bishop, MD

Professor of Medicine

Director, Hematopoietic Stem Cell Transplantation Program

Jason J. Luke, MD, FACP

Assistant Professor of Medicine

Disclosure

The University of Chicago adheres fully to the ACCME Essential Areas, Standards for Commercial Support, and Policies regarding industry support of continuing medical education. Disclosure of the commercial relationships of everyone in a position to control the content of this educational activity has been provided. Speakers are also required to openly disclose discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.

Faculty Presenter Disclosure

Michael R. Bishop, MD is a speaker for Celgene and receives an honorarium.

Jason J. Luke, MD, FACP is on the Ad Board for Amgen and receives an honorarium. Dr. Luke plans to discuss research about the use of immunotherapies: ipilimumab, nivolumab, pembrolizumab.

University of Chicago Center for Continuing Medical Education

The staff of the Center for Continuing Medical Education have no financial arrangements or affiliations to disclose.

Disclaimer

The information presented at this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient's medical condition.

Unapproved Product Use

This educational activity may contain discussion of published or investigational uses of agents that are not indicated by the US Food and Drug Administration. The University of Chicago does not recommend the use of any agent outside the labeled indications. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of The University of Chicago. Please refer to the official prescribing information of each product for discussion of approved indications, contraindications, and warnings.



THE UNIVERSITY OF
CHICAGO
MEDICINE